MRPL3 Prognostic Biomarker Data for Lung Adenocarcinoma

MRPL3 is identified as a prognostic biomarker and therapeutic target in lung adenocarcinoma via a lactylation-disulfidptosis gene signature model and experimental validation. The dataset likely contains gene expression profiles and analysis results from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts. Author Lan Yin published this 16.5 KB document on figshare in May 2026.

Use Cases

• Validate prognostic gene signatures based on lactylation and disulfidptosis pathways mentioned in the description.
• Analyze correlations between MRPL3 expression and tumor stage or immunosuppressive microenvironment features.
• Investigate links between glycolytic-lactate metabolism and cell death evasion based on experimental findings.
• Benchmark new prognostic models against the LASSO regression model described.

Strengths

• Data is derived from authoritative public genomics repositories TCGA and GEO.
• Experimental validation includes both in vitro and in vivo results.
• The prognostic model was evaluated across testing, validation, and external cohorts.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 16.5 KB document, suggesting limited scope or summary data rather than raw expression matrices.

Provenance

Source

The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) cohorts.

Collection Method

Differential expression analysis, correlation analysis, univariate survival analysis, and LASSO regression.

Freshness

Last updated 2026-05-19 05:40:22; freshness should be verified.